CFR heads into its July 30 earnings date with a notable split: analysts are warming up while short sellers are heading for the exit.
The most striking move of the past two weeks is the wave of analyst target upgrades. Multiple firms lifted their price objectives in early July — Barclays moved to $160, Evercore ISI to $166, and Jefferies went further, upgrading its rating outright from Underperform to Hold while raising its target from $135 to $160. Cantor Fitzgerald followed on July 15, bumping its target to $158. The direction of travel is clear: the Street is revising higher into earnings, even if most firms stay neutral on the rating. Not everyone is on board — Morgan Stanley holds an Underweight at $141 and Citigroup keeps a Sell with a $145 target, while Raymond James downgraded to Market Perform at end of June. The mean price target of $158.71 sits close to the current price of $157.38, which tells you the consensus sees fair value roughly here, with pockets of conviction on both sides.
Short sellers have been unwinding positions this week, and the lending market reflects little urgency to press the short side. SI in CFR fell nearly 12% over the past week to 5.4% of the free float — still a meaningful level, but trending lower after spiking in late June and early July when it briefly climbed toward 6%. Borrow is effectively free at 0.50%, and availability is wide open at 628% — meaning there are roughly six shares available to borrow for every one currently lent out. That's well above the year's tightest reading of 505% recorded at end of June. The short score has also drifted down from around 53.5 in early July to 49.5 now, reflecting the easing in short demand. Taken together, positioning looks cautious rather than crowded — the short interest level is moderate, but the retreat and cheap borrow suggest bears aren't adding conviction here.
Options tell a subtler story. The put/call ratio has climbed to 0.196, roughly 1.2 standard deviations above its 20-day average of 0.130 — more defensive than the recent norm, though still modest in absolute terms. The shift is worth noting because it arrived alongside the analyst upgrades rather than against them. The PCR jumped sharply at the start of July after sitting in the 0.07-0.08 range through mid-June, suggesting some investors began buying downside protection even as the analyst community turned more constructive. The 52-week range on the PCR — from 0.047 to 1.56 — puts the current 0.196 reading toward the lower end of the historical range, so this isn't alarm-bell territory.
On valuation, CFR trades at roughly 13.5x trailing earnings and 1.9x book — modest multiples for a Texas franchise with consistent credit discipline. The factor scorecard is mixed: the dividend score ranks in the 90th percentile, EPS surprise sits around the 69th, and 90-day EPS momentum scores 67th. But short-term EPS momentum over 30 days has weakened to the 17th percentile, and the forward earnings growth score is soft at the 27th. The bull case rests on CFR's relationship-banking model and continued market share gains from larger Texas competitors. The bear case points to energy market volatility and rate sensitivity, though the bank's conservative credit culture and organic-only expansion approach limit the downside scenario to macro rather than execution risk.
Earnings on July 30 are the next focus. The most recent print in late April produced a 1.7% one-day decline and a 3% five-day drift lower — a pattern worth monitoring as the Street recalibrates targets closer to fair value and options traders add modest protection ahead of the release.
See the live data behind this article on ORTEX.
Open CFR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
